Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p43
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 43/191)
Character Range: 9954487–9968951

with Authority Required procedures - Streamlined Authority Code 5710
                                                                                                                                                                                                                               Only 1 treatment each year per patient will be PBS-subsidised
C5712               P5712          CN5712           Albendazole                                                                                                                                                                Strongyloidiasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 5712

C5716               P5716          CN5716           Vancomycin                                                                                                                                                                 Endophthalmitis

C5717               P5717          CN5717           Vancomycin                                                                                                                                                                 Endocarditis
                                                                                                                                                                                                                               The treatment must be for prophylaxis; AND
                                                                                                                                                                                                                               Patient must be hypersensitive to penicillin.
C5718               P5718          CN5718           Azithromycin                                                                                                                                                               Urethritis
                                                                                                                                                                                                                               The condition must be uncomplicated and due to Chlamydia trachomatis.
C5719               P5719          CN5719           Asenapine                                                                                                                                                                  Bipolar I disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 5719
                                                                                                                                                                                                                               The treatment must be maintenance therapy; AND
                                                                                                                                                                                                                               The treatment must be as monotherapy.
C5720               P5720          CN5720           Bisacodyl                                                                                                                                                                  Constipation
                                                                                                                                                                                                                               Patient must be receiving long-term nursing care on account of age, infirmity or other condition in a hospital, nursing home or residential facility.
                                                    Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate

C5721               P5721          CN5721           Ondansetron                                                                                                                                                                Nausea and vomiting
                                                                                                                                                                                                                               The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.
C5722               P5722          CN5722           Ciprofloxacin                                                                                                                                                              Bacterial gastroenteritis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures
                                                                                                                                                                                                                               Patient must be severely immunocompromised.
C5727               P5727          CN5727           Acitretin                                                                                                                                                                  Severe disorders of keratinisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 5727

C5729               P5729          CN5729           Bicalutamide                                                                                                                                                               Metastatic (stage D) carcinoma of the prostate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Compliance with Authority Required procedures - Streamlined Authority Code 5729
                                                                                                                                                                                                                               The treatment must be in combination with GnRH (LH-RH) analogue therapy.
                                                    Flutamide

C5731               P5731          CN5731           Medroxyprogesterone                                                                                                                                                        Advanced breast cancer
                                                                                                                                                                                                                               The condition must be hormone receptor positive.
C5732               P5732          CN5732           Benzydamine                                                                                                                                                                Mucositis
                                                                                                                                                                                                                               The condition must be radiation induced.
C5735               P5735          CN5735           Zoledronic acid                                                                                                                                                            Multiple myeloma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 5735

C5740               P5740          CN5740           Dornase alfa                                                                                                                                                               Cystic fibrosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures - Streamlined Authority Code 5740
                                                                                                                                                                                                                               Patient must be 5 years of age or older.
                                                                                                                                                                                                                               Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit.
                                                                                                                                                                                                                               Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease.
                                                                                                                                                                                                                               Initial therapy is limited to 3 months treatment with dornase alfa at a dose of 2.5 mg daily.
                                                                                                                                                                                                                               To be eligible for continued PBS-subsidised treatment with this drug following 3 months of initial treatment
                                                                                                                                                                                                                               (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND
                                                                                                                                                                                                                               (2) the patient or the patient's family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient.
                                                                                                                                                                                                                               Further reassessments must be undertaken